C3TI aims to promote the adoption of pragmatic design in clinical trials and improve coordination and collaboration between CDER and sponsors to effectively support these innovative trials.
Similar Posts
CDER Small Business and Industry Assistance (SBIA) Learn
SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.FDA Rationale for Breakpoints Recognition Decision: Azithromycin and Neisseria gonorrhoeae
FDA Rationale for Breakpoints Recognition Decision: Azithromycin and Neisseria gonorrhoeaeMolecular PharmaGroup LLC. New Providence, NJ. 483 issued 08/11/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 08/11/2025
Short Title (70 char) Molecular PharmaGroup LLC. New Providence, NJ. 483 issued 08/11/2025
FEI Number 3014413265
Firm Name Molecular PharmaGroup LLC
Record Type 483
State NJ
Establishment Type OutsourSunscreen Innovation Act | SIA
The Sunscreen Innovation Act (SIA) was enacted on November 26, 2014 to provide an alternative process for the review of safety and effectiveness of nonprescription sunscreen active ingredients.Baxter Oncology GmbH – 09/26/2025
Baxter Oncology GmbH – 09/26/2025. Country: Germany. Record Type: 483Company Voluntarily Recalls Honey Balsamic Salad Kit Due to Potential Undeclared Sesame and Soy
Salinas, Calif., August 26, 2025 – In response to a recall initiated by Latitude 36 Foods, LLC., Taylor Fresh Foods is voluntarily recalling the Taylor Farms Honey Balsamic Salad Kit 6/8.3oz. because it may contain undeclared sesame and soy allergens. People who have an allergy or severe sensitivity